#1 Clinical Trials Search in Europe

Aaa802

AAA802 is an investigational drug currently being studied in clinical trials for the treatment of advanced prostate cancer. This article will provide an overview of the ongoing research, focusing on a Phase I/II clinical trial called “SatisfACtion” that aims to evaluate the safety, tolerability, and effectiveness of AAA802 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Table of Contents

What is AAA802?

AAA802 is a new investigational drug being studied for the treatment of advanced prostate cancer[1]. Specifically, it’s being tested in men with metastatic castration-resistant prostate cancer (mCRPC) that is PSMA-positive. Let’s break down these terms:

  • Metastatic means the cancer has spread beyond the prostate to other parts of the body.
  • Castration-resistant means the cancer continues to grow even when the levels of male hormones (like testosterone) are reduced to very low levels.
  • PSMA-positive refers to cancer cells that have high levels of a protein called Prostate-Specific Membrane Antigen (PSMA) on their surface.

How does AAA802 work?

AAA802 is a type of treatment called targeted radioligand therapy. It works by combining two important components[1]:

  1. A molecule that specifically targets PSMA on prostate cancer cells.
  2. A radioactive substance called Actinium-225 (225Ac).

When injected into the body, AAA802 seeks out prostate cancer cells with PSMA and delivers the radioactive substance directly to them. This targeted approach aims to kill cancer cells while minimizing damage to healthy tissues.

Who is AAA802 for?

The clinical trial is studying AAA802 in two groups of patients[1]:

  1. Men with mCRPC who have previously received treatment with another radioligand therapy called 177Lu-PSMA.
  2. Men with mCRPC who have not received 177Lu-PSMA therapy before.

All patients in the trial must have tried other treatments for prostate cancer, including hormone therapy and chemotherapy, before being eligible for AAA802.

Clinical Trial Details

The clinical trial for AAA802 is called “SatisfACtion” and is a Phase I/II study[1]. This means it’s an early-stage trial designed to:

  • Find the right dose of AAA802 that is safe and effective (Phase I)
  • Test how well AAA802 works in treating mCRPC (Phase II)

The trial is “open-label,” which means both patients and doctors know which treatment is being given. It’s also “multi-center,” indicating that it’s being conducted at multiple hospitals or clinics.

Eligibility Criteria

To participate in the AAA802 trial, patients must meet certain criteria[1]. Some key eligibility requirements include:

  • Being at least 18 years old
  • Having confirmed metastatic prostate cancer that is castration-resistant and PSMA-positive
  • Having tried hormone therapy and chemotherapy for prostate cancer
  • Having adequate organ function (bone marrow, liver, and kidneys)
  • Not having certain heart conditions or other serious medical issues

There are additional specific criteria that doctors will use to determine if a patient is eligible for the trial.

Potential Benefits and Risks

As with any experimental treatment, AAA802 may have both potential benefits and risks[1]:

Potential benefits:

  • It may help slow or stop the growth of prostate cancer
  • It’s designed to target cancer cells specifically, potentially reducing side effects

Potential risks:

  • Side effects from the radiation, which could affect bone marrow, kidneys, or other organs
  • Unknown long-term effects, as this is a new treatment

The clinical trial is designed to carefully monitor patients for any side effects or safety concerns.

Quality of Life Considerations

An important aspect of the AAA802 trial is assessing how the treatment affects patients’ quality of life[1]. The researchers will use several questionnaires to measure things like:

  • Overall health status
  • Prostate cancer-specific symptoms and concerns
  • Pain levels

This information will help doctors and future patients understand not just how effective AAA802 is at treating cancer, but also how it impacts day-to-day life during treatment.

Aspect Details
Drug Name AAA802 (225Ac-PSMA-R2)
Trial Name SatisfACtion
Trial Phase Phase I/II
Target Condition PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
Primary Objectives Assess safety, tolerability, and anti-tumor activity
Patient Groups 1) Previously treated with 177Lu-PSMA therapy
2) Not previously treated with 177Lu-PSMA therapy
Key Eligibility Criteria Adults ≥18 years, confirmed mCRPC, PSMA-positive disease, adequate organ function
Administration Route Intravenous injection/infusion
Primary Endpoints Dose-limiting toxicities, adverse events, overall response rate
Secondary Endpoints Safety, tolerability, pharmacokinetics, quality of life measures

FAQ

  • What is AAA802? AAA802 is an investigational drug being studied for the treatment of advanced prostate cancer. It is specifically designed to target PSMA (Prostate-Specific Membrane Antigen) positive cancer cells.
  • What type of cancer is being targeted in this clinical trial? The clinical trial is focusing on PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), which is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy.
  • What are the main objectives of the SatisfACtion clinical trial? The main objectives are to determine the safety and tolerability of AAA802, find the recommended dose for further studies, and evaluate its anti-tumor activity in patients who have or have not previously received a specific type of treatment called 177Lu-labelled PSMA-targeted radioligand therapy.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with confirmed PSMA-positive mCRPC, who have received prior treatments and show evidence of disease progression. They must also meet specific criteria for organ function and overall health status.
  • How is AAA802 administered in the trial? AAA802 is administered as a solution for injection or infusion, given intravenously (directly into the bloodstream). The exact dosing schedule and amount will be determined during the trial.

Ongoing Clinical Trials on Aaa802

  • Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): An advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy (also called androgen deprivation therapy).
  • PSMA (Prostate-Specific Membrane Antigen): A protein found on the surface of prostate cancer cells, which is used as a target for certain cancer treatments and imaging techniques.
  • Radioligand Therapy (RLT): A type of cancer treatment that uses radioactive substances attached to drugs that specifically target cancer cells.
  • Phase I/II Clinical Trial: A study that combines initial testing of a new drug's safety (Phase I) with early evaluation of its effectiveness (Phase II).
  • Dose Escalation: A process in clinical trials where the dose of a drug is gradually increased to find the optimal balance between effectiveness and side effects.
  • Dose Expansion: A phase in clinical trials where the selected dose from the escalation phase is given to a larger group of patients to further evaluate its effects.
  • Adverse Events (AEs): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, which may or may not be related to the treatment being studied.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Quality of Life (QoL): A measure of a patient's overall well-being and ability to function in daily life during and after treatment.

References

  1. http://clinicaltrials.eu/trial/study-of-225acac-psma-r2-for-men-with-advanced-prostate-cancer-previously-treated-or-not-with-177lu-psma-therapy/